Update on castrate-resistant prostate cancer: 2010

Current Opinion in Oncology

Volumn 22, Issue 3, 2010, Pages 263-267

  Lassi, Kiran ^a   Dawson, Nancy A ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Castrate resistant prostate cancer; Circulating tumor markers; Immunotherapy

Indexed keywords

ABIRATERONE; ANTIANDROGEN; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; CABAZITAXEL; DOCETAXEL; EPOTHILONE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; IXABEPILONE; MDV 3100; MITOXANTRONE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; SORAFENIB; SUNITINIB; TUMOR MARKER; UNCLASSIFIED DRUG; XRP 6258;

ANOREXIA; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CASTRATION; CLINICAL DECISION MAKING; DIARRHEA; FATIGUE; HEPATITIS; HUMAN; MORBIDITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RASH; REVIEW; TUMOR VASCULARIZATION; UNITED STATES;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

EID: 77951445053     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283380939     Document Type: Review

References (35)

1. American Cancer Society. What are the key statistics about prostate cancer. http://www.cancer.org
2. Beardsley EK, Chi KN. Systemic therapy after first linedocetaxel in metastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care 2008; 2:1 61-166.
3. http://www.oncology.sanofi-aventis.com
4. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110:556-563.
5. Hussain M, Tangen CM, Lara PN Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005; 23:8724-8729.
6. Beardsley E, Saad F, Venner F, Winquist Y. A phase II study of patupilone in patients (Pts) in metastatic castrate resistant prostate cancer (CRPC) who have progressed after docetaxel. J Clin Oncol 2009 [abstract 5139].
7. Chi KN, Beardsley EK, Venner PM, et al. A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel. J Clin Oncol 2008 [Abstract 5166].
8. De Bono JS, Attard G, Reid AH, et al. Antitumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pretreated castration resistant prostate cancer (CRPC). J Clin Oncol 2008 [Abstract 5005].
9. Danila DC, Rathkopf DE, Morris MJ, et al. Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy. J Clin Oncol 2008 [abstract 5019].
10. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP 17 with abiraterone acetate is highly active in the treatment of castrate-resistant prostate cancer. J Clin Oncol 2009; 27:3742-3748.
11. Scher HI, Beer TM, Higano CS, et al. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer. J Clin Oncol 2009 [abstract 5011].
12. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-3094.
13. http://www.dendreon.com/pipeline/sipuleucel-t/
14. Corman J, Small E, Smith D, et al. Immunotherapy with GVAX® vaccine for prostate cancer improves predicted survival in metastatic hormone refractory prostate cancer: results from two phase 2 studies. Proceedings from the American Urological Association Annual Meeting. Atlanta, Georgia. 2006 [abstract 976]
15. website: http://www.drugs.com/news/cell-genesys-halts-vital-2-gvax-trial- ad vanced-prostate-cancer-13371.html
16. Small E, Demkow T, Gerritsen WR, et al. A phase III study of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate can cer (CRPC). Genitourinary Cancers Symposium. ASCO 2009 [Abstract 7].
17. Slovin SF, BeerTM, Higano CS, et al. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) abstr 5138. J Clin Oncol 2009; 27:15s.
18. Gerritsen W, Van Den Eertwegh AJ, De Gruijl TD, et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunother apy in combination with a fully human anti-CTLA antibody (MDX-010, ipili mumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC) Data presented at the 3rd annual ASCO Prostate Cancer Sympo sium, Orlando, Florida, February 22-24, 2007.
19. Danila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13:7053-7058. (Pubitemid 350276887)
20. Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration resistant prostate cancer. Clin Cancer Res 2007; 13:2023-2029.
21. De Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14:6302-6309.
22. Fleisher D, Danila C, Leversha M, et al. Circulating tumor cells (CTC) in patients with metastatic castration-resistant prostate cancer (CRPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy. J Clin Oncol 2009; 27:15s [Abstract 5049].
23. Melynk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing antivascular endothelial growth inhibits further growth of established prostate cancer and metastases in a preclinical model. J Urol 1999; 161:960-963.
24. Di Lorenzo G, Figg W, Fossa S, et al. Giuliano combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 54:1089-1096.
25. Sonpavde G, Periman PO, Bernold, D, et al. Sutinib malate for metastatic castration-resistant prostate cancer after docetaxel based chemotherapy. Ann Oncol 2009 [Epub ahead of print].
26. Dahut WL, Scripture C, Posadas E, et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14:209-214.
27. Safarenijad MR. Safety and efficacy of sorafenib with castrate resistant prostate cancer. Urologic Oncol 2008; 28:21-27.
28. Aragon-Ching JB, Jain L, Gulley JL, et al. Final analysis of a phase II trial using sorafenib in castrate resistant prostate cancer. BJUInt 2009; 103:1636-1640.
29. Akhavan A, McHugh KH, Guruli G, et al. Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia 2006; 8:725-732.
30. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1:944-949.
31. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110:1959-1966.
32. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. J Clin Oncol 2007; 25 (18S):5018.
33. James N, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic: a double-blind, placebo-controlled, randomized, phase 2 trial. Eur Urology 2008; 55:1112-1123.
34. Chi KN, Hotte SJ, Yu E, et al. A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol 2007; 25 [abstract 5069].
35. Saad F, Hotte SJ, North SA, et al. A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy. J Clin Oncol 2008; 26 [abstract 5002].